Caliper Teams with Horizon on Oncology Cell Lines

Apr 09, 2008

NEW YORK (GenomeWeb News) – Caliper Life Sciences today announced that it is incorporating Horizon Discovery’s oncology cell lines into its offerings from Caliper Discovery Alliances and Services.

According to Hopkinton, Mass.-based Caliper, the deal provides CDAS with unique, genetically defined, and isogenic human cancer cell lines that will enable researchers to better identify and characterize personalized drugs targeted at specific subsets of patients.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

An Expensive Deal

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Figuring Out Who It'll Work For

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

This Week in Nature

In Nature this week: paternal age associated with de novo mutations in children, and more.

Ye Old P-Value

Nature News writes that researchers are still wrangling over the role of the p-value.

Main menu